Symbols / KAPA
KAPA Chart
About
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, and a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions; KROS 201 that activates the T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor with mechanisms of action resulting from blocking intranuclear localization of RelA, a key component of the NF-KB pathway, as well as targets tumor cells in RelA/p65 biomarker positive solid tumors; and KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13 reversing tumor associated macrophage inhibition, and blocks the IL4/IL13 cytokine immune receptors for triple negative breast cancer. It also develops ENV 105, an antibody therapeutic for the prostate cancer patients resistant to androgen-targeted therapy, which is in Phase 2 clinical trial; and ENV 205, an antibody fragment that targets mitochondrial DNA. The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 11.87M |
| Enterprise Value | 6.34M | Income | -5.06M | Sales | — |
| Book/sh | 0.37 | Cash/sh | 0.27 | Dividend Yield | — |
| Payout | 0.00% | Employees | 1 | IPO | — |
| P/E | — | Forward P/E | -1.73 | PEG | — |
| P/S | — | P/B | 1.55 | P/C | — |
| EV/EBITDA | -1.16 | EV/Sales | — | Quick Ratio | 13.87 |
| Current Ratio | 16.56 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.31 | EPS next Y | -0.33 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 13:00 | ROA | -53.59% |
| ROE | -92.07% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 20.74M |
| Shs Float | 11.83M | Short Float | 1.02% | Short Ratio | 0.80 |
| Short Interest | — | 52W High | 2.11 | 52W Low | 0.40 |
| Beta | — | Avg Volume | 147.24K | Volume | 22.68K |
| Target Price | $8.33 | Recom | None | Prev Close | $0.56 |
| Price | $0.57 | Change | 2.57% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.33
Mean price target
2. Current target
$0.57
Latest analyst target
3. DCF / Fair value
$-3.14
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.57
Low
$4.00
High
$12.00
Mean
$8.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-19 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-11-04 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-10-20 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-10-07 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-09-19 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-07-16 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-06-04 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-04-17 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-04-03 | init | HC Wainwright & Co. | — → Buy | $12 |
| 2025-03-31 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-03-27 | init | Maxim Group | — → Buy | $4 |
| 2025-03-20 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-02-26 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-02-18 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-02-12 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-01-22 | main | D. Boral Capital | Buy → Buy | $9 |
| 2024-11-14 | main | D. Boral Capital | Buy → Buy | $9 |
| 2024-10-14 | init | EF Hutton | — → Buy | $9 |
- Kairos Pharma stock rises after selection for ESMO Congress presentation - Investing.com ue, 07 Oct 2025 07
- Kairos Pharma Stock Soars After Positive Interim Results From Phase 2 Trial Of ENV-105 - Nasdaq ue, 15 Jul 2025 07
- Kairos Pharma’s Surprising Stock Surge: What’s the Move? - StocksToTrade ue, 15 Jul 2025 07
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga ue, 03 Feb 2026 08
- 5 Biotech Stocks To Watch Ahead Of Major Clinical Trial Data Readouts In September 2025 - RTTNews Wed, 27 Aug 2025 07
- Smurfit Kappa (SK3.IR EURONEXT) pre-market: EUR 41.44 on 27 Jan 2026, most active with volume surge - Meyka ue, 27 Jan 2026 08
- Kairos Pharma stock soars after positive safety data for cancer drug - Investing.com ue, 15 Jul 2025 07
- Is KAPA stock a top pick in earnings season - July 2025 Setups & Daily Profit Focused Screening - mfd.ru Mon, 09 Feb 2026 00
- Maxim Group Initiates Coverage of Kairos Pharma (KAPA) with Buy Recommendation - Nasdaq hu, 27 Mar 2025 07
- KAPA Stock Price and Chart — AMEX:KAPA - TradingView Mon, 16 Sep 2024 19
- 12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga hu, 22 Jan 2026 08
- Kairos goes public with $6M IPO to fund trials of lead cancer drug - Fierce Biotech ue, 17 Sep 2024 07
- KAPA IPO News - Micro-cap cancer biotech Kairos Pharma prices IPO at $4 - renaissancecapital.com ue, 17 Sep 2024 07
- Growth or Bubble? Decoding Kairos Pharma’s Surge - StocksToTrade Wed, 16 Jul 2025 07
- CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline - Yahoo Finance Mon, 28 Jul 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 19084 | — | — | Stock Award(Grant) at price 0.00 per share. | SINGHVI RAHUL | Director | — | 2025-10-08 00:00:00 | D |
| 1 | 190840 | — | — | Stock Award(Grant) at price 0.00 per share. | YU JOHN S | Chief Executive Officer | — | 2025-10-08 00:00:00 | D |
| 2 | 29084 | — | — | Stock Award(Grant) at price 0.00 per share. | KEYOUNG HANSOO MICHAEL | Director | — | 2025-10-08 00:00:00 | D |
| 3 | 152672 | — | — | Stock Award(Grant) at price 0.00 per share. | SAMUELSON DOUG | Chief Financial Officer | — | 2025-10-08 00:00:00 | D |
| 4 | 171756 | — | — | Stock Award(Grant) at price 0.00 per share. | BHOWMICK NEIL PH.D. | Officer | — | 2025-10-08 00:00:00 | D |
| 5 | 29084 | — | — | Stock Award(Grant) at price 0.00 per share. | BAE HYUN W. M.D. | Director | — | 2025-10-08 00:00:00 | D |
| 6 | 152672 | — | — | Stock Award(Grant) at price 0.00 per share. | MURALI RAMACHANDRAN PH.D. | Officer | — | 2025-10-08 00:00:00 | D |
| 7 | 14000 | — | — | Stock Award(Grant) at price 0.00 per share. | YU JOHN S | Chief Executive Officer | — | 2024-12-31 00:00:00 | D |
| 8 | 14000 | — | — | Stock Award(Grant) at price 0.00 per share. | BHOWMICK NEIL PH.D. | Officer | — | 2024-12-31 00:00:00 | D |
| 9 | 14000 | — | — | Stock Award(Grant) at price 0.00 per share. | MURALI RAMACHANDRAN PH.D. | Officer | — | 2024-12-31 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -2.85M | -1.55M | -431.00K | -1.88M |
| TotalUnusualItems | 599.00K | 0.00 | ||
| TotalUnusualItemsExcludingGoodwill | 599.00K | 0.00 | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -2.60M | -1.81M | -1.05M | -2.15M |
| ReconciledDepreciation | 160.00K | 160.00K | 160.00K | 98.00K |
| EBITDA | -2.25M | -1.55M | -431.00K | -1.88M |
| EBIT | -2.41M | -1.71M | -591.00K | -1.98M |
| NetInterestIncome | -859.00K | -98.00K | -479.00K | -202.00K |
| InterestExpense | 189.00K | 98.00K | 459.00K | 164.00K |
| NormalizedIncome | -3.20M | -1.81M | -1.05M | -2.15M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -2.60M | -1.81M | -1.05M | -2.15M |
| TotalExpenses | 2.34M | 1.71M | 571.00K | 1.94M |
| TotalOperatingIncomeAsReported | -2.34M | -1.71M | -571.00K | -1.94M |
| DilutedAverageShares | 11.36M | 11.22M | 10.84M | 10.85M |
| BasicAverageShares | 11.36M | 11.22M | 10.84M | 10.85M |
| DilutedEPS | -0.23 | -0.16 | -0.10 | -0.10 |
| BasicEPS | -0.23 | -0.16 | -0.10 | -0.10 |
| DilutedNIAvailtoComStockholders | -2.60M | -1.81M | -1.05M | -2.15M |
| NetIncomeCommonStockholders | -2.60M | -1.81M | -1.05M | -2.15M |
| NetIncome | -2.60M | -1.81M | -1.05M | -2.15M |
| NetIncomeIncludingNoncontrollingInterests | -2.60M | -1.81M | -1.05M | -2.15M |
| NetIncomeContinuousOperations | -2.60M | -1.81M | -1.05M | -2.15M |
| PretaxIncome | -2.60M | -1.81M | -1.05M | -2.15M |
| OtherIncomeExpense | 599.00K | |||
| SpecialIncomeCharges | 599.00K | 0.00 | ||
| OtherSpecialCharges | -599.00K | |||
| NetNonOperatingInterestIncomeExpense | -859.00K | -98.00K | -479.00K | -202.00K |
| TotalOtherFinanceCost | 670.00K | 56.00K | 20.00K | 38.00K |
| InterestExpenseNonOperating | 189.00K | 98.00K | 459.00K | 164.00K |
| OperatingIncome | -2.34M | -1.71M | -571.00K | -1.94M |
| OperatingExpense | 2.34M | 1.71M | 571.00K | 1.94M |
| DepreciationAmortizationDepletionIncomeStatement | 160.00K | 160.00K | 160.00K | 98.00K |
| DepreciationAndAmortizationInIncomeStatement | 160.00K | 160.00K | 160.00K | 98.00K |
| Amortization | 160.00K | 160.00K | 160.00K | 98.00K |
| AmortizationOfIntangiblesIncomeStatement | 160.00K | 160.00K | 160.00K | 98.00K |
| ResearchAndDevelopment | 414.00K | 82.00K | 87.00K | 183.00K |
| SellingGeneralAndAdministration | 1.77M | 1.47M | 324.00K | 1.66M |
| GeneralAndAdministrativeExpense | 1.77M | 1.47M | 324.00K | 1.66M |
| OtherGandA | 1.40M | 530.00K | 304.00K | 1.35M |
| InsuranceAndClaims | 151.00K | 29.00K | 20.00K | 13.00K |
| SalariesAndWages | 219.00K | 913.00K | 0.00 | 300.00K |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 13.74M | 12.84M | 12.84M | 12.84M |
| ShareIssued | 13.74M | 12.84M | 12.84M | 12.84M |
| NetDebt | 545.00K | 145.00K | 307.00K | |
| TotalDebt | 638.00K | 582.00K | 380.00K | |
| TangibleBookValue | 4.55M | -2.46M | -1.72M | -1.87M |
| InvestedCapital | 4.78M | -1.44M | -597.00K | -787.00K |
| WorkingCapital | 3.18M | -2.30M | -1.20M | -1.87M |
| NetTangibleAssets | 4.55M | -2.46M | -1.72M | -1.87M |
| CommonStockEquity | 4.78M | -2.08M | -1.18M | -1.17M |
| TotalCapitalization | 4.78M | -1.44M | -597.00K | -1.17M |
| TotalEquityGrossMinorityInterest | 4.78M | -2.08M | -1.18M | -1.17M |
| StockholdersEquity | 4.78M | -2.08M | -1.18M | -1.17M |
| RetainedEarnings | -8.81M | -6.21M | -4.40M | -3.35M |
| AdditionalPaidInCapital | 13.58M | 4.12M | 3.21M | 2.17M |
| CapitalStock | 14.00K | 11.00K | 10.00K | 10.00K |
| CommonStock | 14.00K | 11.00K | 10.00K | 10.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 992.00K | 3.04M | 2.21M | 1.94M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 638.00K | 582.00K | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 638.00K | 582.00K | ||
| LongTermDebt | 638.00K | 582.00K | ||
| CurrentLiabilities | 992.00K | 2.40M | 1.63M | 1.94M |
| CurrentDebtAndCapitalLeaseObligation | 380.00K | |||
| CurrentDebt | 380.00K | |||
| OtherCurrentBorrowings | 350.00K | |||
| CurrentNotesPayable | 0.00 | 30.00K | ||
| PayablesAndAccruedExpenses | 992.00K | 2.40M | 1.63M | 1.56M |
| Payables | 992.00K | 2.40M | 1.63M | 1.56M |
| DuetoRelatedPartiesCurrent | 0.00 | 4.00K | 4.00K | 14.00K |
| AccountsPayable | 992.00K | 2.40M | 1.63M | 1.55M |
| TotalAssets | 5.77M | 965.00K | 1.04M | 775.00K |
| TotalNonCurrentAssets | 1.60M | 864.00K | 599.00K | 702.00K |
| NonCurrentDeferredAssets | 1.38M | 482.00K | 57.00K | 0.00 |
| GoodwillAndOtherIntangibleAssets | 222.00K | 382.00K | 542.00K | 702.00K |
| OtherIntangibleAssets | 222.00K | 382.00K | 542.00K | 702.00K |
| CurrentAssets | 4.17M | 101.00K | 437.00K | 73.00K |
| OtherCurrentAssets | 38.00K | 8.00K | ||
| PrepaidAssets | 2.86M | 0.00 | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 1.27M | 93.00K | 437.00K | 73.00K |
| CashAndCashEquivalents | 1.27M | 93.00K | 437.00K | 73.00K |
| CashFinancial | 1.27M | 93.00K | 437.00K | 73.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -3.96M | 81.00K | -353.00K | -412.00K |
| RepaymentOfDebt | -142.00K | 0.00 | -30.00K | -20.00K |
| IssuanceOfDebt | 142.00K | 0.00 | 925.00K | 350.00K |
| IssuanceOfCapitalStock | 5.52M | 0.00 | 0.00 | 250.00K |
| InterestPaidSupplementalData | 3.00K | 0.00 | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 1.27M | 93.00K | 437.00K | 73.00K |
| BeginningCashPosition | 93.00K | 437.00K | 73.00K | 14.00K |
| ChangesInCash | 1.18M | -344.00K | 364.00K | 59.00K |
| FinancingCashFlow | 5.13M | -425.00K | 717.00K | 580.00K |
| CashFlowFromContinuingFinancingActivities | 5.13M | -425.00K | 717.00K | 580.00K |
| NetOtherFinancingCharges | -390.00K | -425.00K | -178.00K | |
| NetCommonStockIssuance | 5.52M | 0.00 | 0.00 | 250.00K |
| CommonStockIssuance | 5.52M | 0.00 | 0.00 | 250.00K |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | 895.00K | 330.00K |
| NetShortTermDebtIssuance | -20.00K | |||
| ShortTermDebtPayments | -20.00K | |||
| ShortTermDebtIssuance | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | 0.00 | 895.00K | 330.00K |
| LongTermDebtPayments | -142.00K | 0.00 | -30.00K | -20.00K |
| LongTermDebtIssuance | 142.00K | 0.00 | 925.00K | 350.00K |
| InvestingCashFlow | 0.00 | -109.00K | ||
| CashFlowFromContinuingInvestingActivities | 0.00 | -109.00K | ||
| NetOtherInvestingChanges | -109.00K | |||
| OperatingCashFlow | -3.96M | 81.00K | -353.00K | -412.00K |
| CashFlowFromContinuingOperatingActivities | -3.96M | 81.00K | -353.00K | -412.00K |
| ChangeInWorkingCapital | -1.98M | 764.00K | 129.00K | 1.19M |
| ChangeInOtherWorkingCapital | -2.36M | |||
| ChangeInPayablesAndAccruedExpense | 404.00K | 772.00K | 129.00K | 1.19M |
| ChangeInPrepaidAssets | -2.39M | -8.00K | 0.00 | |
| OtherNonCashItems | 225.00K | 969.00K | 408.00K | 144.00K |
| StockBasedCompensation | 218.00K | 0.00 | 0.00 | 300.00K |
| DepreciationAmortizationDepletion | 160.00K | 160.00K | 160.00K | 98.00K |
| DepreciationAndAmortization | 160.00K | 160.00K | 160.00K | 98.00K |
| AmortizationCashFlow | 160.00K | 160.00K | 160.00K | 98.00K |
| AmortizationOfIntangibles | 160.00K | 160.00K | 160.00K | 98.00K |
| OperatingGainsLosses | 29.00K | |||
| GainLossOnInvestmentSecurities | 29.00K | |||
| NetIncomeFromContinuingOperations | -2.60M | -1.81M | -1.05M | -2.15M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for KAPA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|